CNS Pharmaceuticals, Inc.

2.15 USD
+0.13 (+6.44%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

CNS Pharmaceuticals, Inc. stock is up 47.26% since 30 days ago. The next earnings date is Apr 1, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 0% of the previous 4 December’s closed higher than November.

About CNS Pharmaceuticals, Inc.

CNS Pharmaceuticals, Inc. engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, an anthracycline that is in Phase I and II clinical trials.